1. Home
  2. FOA vs VYGR Comparison

FOA vs VYGR Comparison

Compare FOA & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Finance of America Companies Inc.

FOA

Finance of America Companies Inc.

HOLD

Current Price

$22.26

Market Cap

221.6M

Sector

Finance

ML Signal

HOLD

Logo Voyager Therapeutics Inc.

VYGR

Voyager Therapeutics Inc.

HOLD

Current Price

$3.23

Market Cap

203.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOA
VYGR
Founded
2013
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
221.6M
203.6M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
FOA
VYGR
Price
$22.26
$3.23
Analyst Decision
Buy
Strong Buy
Analyst Count
2
2
Target Price
$26.00
$16.50
AVG Volume (30 Days)
48.1K
546.3K
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
216.95
N/A
EPS
0.41
N/A
Revenue
$497,432,000.00
$10,135,000.00
Revenue This Year
$0.58
$34.04
Revenue Next Year
$6.91
$7.92
P/E Ratio
$53.66
N/A
Revenue Growth
47.09
N/A
52 Week Low
$15.77
$2.94
52 Week High
$29.79
$5.55

Technical Indicators

Market Signals
Indicator
FOA
VYGR
Relative Strength Index (RSI) 46.01 50.65
Support Level $22.10 $2.95
Resistance Level $24.03 $3.28
Average True Range (ATR) 1.18 0.15
MACD -0.19 0.04
Stochastic Oscillator 27.38 75.95

Price Performance

Historical Comparison
FOA
VYGR

About FOA Finance of America Companies Inc.

Finance of America Companies Inc provides home equity-based financing solutions for modern retirement and offers capital markets and portfolio management capabilities to optimize loan distribution to investors. The Company operates through two segments: Retirement Solutions and Portfolio Management. The Retirement Solutions segment handles loan origination, including HECM and non-agency reverse mortgage loans, generating revenue from origination fees and initial gains, with loans transferred to the Portfolio Management segment. The Portfolio Management segment, which generates the majority of revenue, provides securitization, loan sales, risk management, and asset management services, and earns revenue from net interest income, fair value changes, and servicing-related income.

About VYGR Voyager Therapeutics Inc.

Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.

Share on Social Networks: